Skip to main content

New Molecular-Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis

Objective

The development of novel technologies to diagnose and clinically treat invasive Aspergillus fumigatus infections is the scope of this research consortium. A. fumigatus is a ubiquitous mould whose spores are airborne and thus frequently inhaled. Humans with impaired immunity, e.g. those with haematological malignancies or bone marrow transplant recipients, are at a dramatically increased risk of severe, invasive A. fumigatus infection known as invasive aspergillosis (IA). IA is a rare disease in Europe but causes tremendous costs to the public health sector. Currently definitive diagnosis of IA is only obtained at autopsy or relies on invasive biopsy, an extremely unpleasant procedure which is not always applicable in suffering patients. Thus, a convenient, fast and specific diagnosis of IA is not available forcing clinicians to administer antifungal drugs on spec if a standard antibiotic treatment failed to reduce fever in risk patients. It would be of high financial benefit for clinics and has the potential to increase the survival rates of immuno-compromised patients, if a definitive diagnosis of IA could be obtained early and its response to treatment be monitored. This would allow applying the correct therapy at a dose and duration exactly tailored to patient needs. Equally important is the development of new treatment options which can replace existing systemic antifungal drugs with their known severe side effects. The approach of the consortium is to develop new disease specific tracers based on monoclonal antibodies along with the combined molecular imaging technologies PET/MR and PET/CT. Newly developed tracers shall then be functionalised by a combined labelling with radio-isotopes allowing diagnostic PET imaging but also immuno-radiotherapy, thus representing truly anti-infectious theranostics. This would provide a framework for new tools in the management not only of this rare but life-threatening mycosis but principally also for other infectious hazards.

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Coordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Address
Geschwister-scholl-platz
72074 Tuebingen
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 042 973,65
Administrative Contact
Bernd Pichler (Prof.)

Participants (5)

UNIVERSITAETSKLINIKUM ESSEN
Germany
EU contribution
€ 1 110 540,34
Address
Hufelandstrasse 55
45147 Essen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Matthias Gunzer (Prof.)
ISCA DIAGNOSTICS LIMITED
United Kingdom
EU contribution
€ 894 190,01
Address
Tregolis Road Lowin House
TR1 2NA Truro
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Robert Misselbrook (Mr.)
CHEMATECH SAS
France
EU contribution
€ 1 006 110
Address
Rue Du Bas De Chanot 7
21800 Chevigny Saint Sauveur
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frédéric Boschetti (Dr.)
PAUL SCHERRER INSTITUT
Switzerland
EU contribution
€ 531 350
Address
Forschungstrasse 111
5232 Villigen Psi
Activity type
Research Organisations
Administrative Contact
Irene Walthert (Mrs.)
DANMARKS TEKNISKE UNIVERSITET
Denmark
EU contribution
€ 402 377
Address
Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mikael Jensen (Prof.)